Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acthar Gel in Pulmonary Sarcoidosis
NCT02523092Phase 4Terminated
- Sponsor
- University of California, San Francisco
- Start
- Nov 2022
- Primary completion
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of repository corticotropin injection in sarcoidosis, sponsored by University of California, San Francisco. Primary endpoint: Decrease in Blood CXCL9 Levels by 50% at 6 months. Started Nov 2022; status: terminated.
02
Drugs
repository corticotropin injection
03
Conditions
sarcoidosis
Beyond the preview
Go deeper on NCT02523092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02523092.